[{"address1": "401 Professional Drive", "address2": "Suite 260", "city": "Gaithersburg", "state": "MD", "zip": "20879", "country": "United States", "phone": "(240) 403-4212", "website": "https://www.shuttlepharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.", "fullTimeEmployees": 8, "maxAge": 86400, "priceHint": 4, "previousClose": 0.408, "open": 0.41, "dayLow": 0.3732, "dayHigh": 0.4196, "regularMarketPreviousClose": 0.408, "regularMarketOpen": 0.41, "regularMarketDayLow": 0.3732, "regularMarketDayHigh": 0.4196, "volume": 19549, "regularMarketVolume": 19549, "averageVolume": 52172, "averageVolume10days": 48290, "averageDailyVolume10Day": 48290, "bid": 0.287, "ask": 0.5116, "bidSize": 200, "askSize": 200, "marketCap": 6267856, "fiftyTwoWeekLow": 0.35, "fiftyTwoWeekHigh": 1.27, "fiftyDayAverage": 0.42832, "twoHundredDayAverage": 0.47215, "currency": "USD", "enterpriseValue": 3364527, "floatShares": 9911338, "sharesOutstanding": 16794900, "sharesShort": 40753, "sharesShortPriorMonth": 73000, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0023999999, "heldPercentInsiders": 0.44441003, "heldPercentInstitutions": 0.01705, "shortRatio": 1.79, "shortPercentOfFloat": 0.004, "impliedSharesOutstanding": 16794900, "bookValue": 0.164, "priceToBook": 2.2756097, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -7348657, "trailingEps": -0.47, "enterpriseToEbitda": -0.588, "52WeekChange": -0.64811325, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SHPH", "underlyingSymbol": "SHPH", "shortName": "Shuttle Pharmaceuticals Holding", "longName": "Shuttle Pharmaceuticals Holdings, Inc.", "firstTradeDateEpochUtc": 1661952600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "7d533843-75d5-319f-b923-9ea3e624e2b7", "messageBoardId": "finmb_319499082", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.3732, "recommendationKey": "none", "totalCash": 4187879, "totalCashPerShare": 0.249, "ebitda": -5725214, "totalDebt": 1284552, "quickRatio": 2.82, "currentRatio": 2.962, "debtToEquity": 46.517, "returnOnAssets": -0.47172, "returnOnEquity": -1.5202099, "freeCashflow": -2904725, "operatingCashflow": -5482248, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]